Helena A. K. Lapatto,Minna Kuusela,Aino Heikkinen,Maheswary Muniandy,Birgitta W. van der Kolk,Swetha Gopalakrishnan,Noora Pöllänen,Martin Sandvik,Mark S. Schmidt,Sini Heinonen,Sina Saari,Juho Kuula,Antti Hakkarainen,Janne Tampio,Tuure Saarinen,Marja-Riitta Taskinen,Nina Lundbom,Per-Henrik Groop,Marja Tiirola,Pekka Katajisto,Marko Lehtonen,Charles Brenner,Jaakko Kaprio,Satu Pekkala,Miina Ollikainen,Kirsi H. Pietiläinen,Eija Pirinen

Abstract:Nicotinamide adenine dinucleotide (NAD + ) precursor nicotinamide riboside (NR) has emerged as a promising compound to improve obesity-associated mitochondrial dysfunction and metabolic syndrome in mice. However, most short-term clinical trials conducted so far have not reported positive outcomes. Therefore, we aimed to determine whether long-term NR supplementation boosts mitochondrial biogenesis and metabolic health in humans. Twenty body mass index (BMI)–discordant monozygotic twin pairs were supplemented with an escalating dose of NR (250 to 1000 mg/day) for 5 months. NR improved systemic NAD + metabolism, muscle mitochondrial number, myoblast differentiation, and gut microbiota composition in both cotwins. NR also showed a capacity to modulate epigenetic control of gene expression in muscle and adipose tissue in both cotwins. However, NR did not ameliorate adiposity or metabolic health. Overall, our results suggest that NR acts as a potent modifier of NAD + metabolism, muscle mitochondrial biogenesis and stem cell function, gut microbiota, and DNA methylation in humans irrespective of BMI.

Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study